News

September 25, 2019

Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma

News

CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA) as a potential treatment of relapsed or refractory ... Read more

September 23, 2019

Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows

News

Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases the proportion of people with multiple myeloma who experience ... Read more

September 20, 2019

Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma

News

GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma ... Read more

September 18, 2019

Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma

News

Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The ... Read more

September 13, 2019

Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma

News

Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective therapy against multiple myeloma, a ... Read more

September 11, 2019

Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’

News

Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S. The kits, which are meant to ... Read more

September 9, 2019September 13, 2019

Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma

News

The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated ... Read more

September 6, 2019September 10, 2019

Israeli Breakthroughs Credited for Early Progress in Treating Multiple Myeloma

News

Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age of 65. At the time, ... Read more

September 4, 2019

FDA Grants Orphan Drug Designation to CARsgen’s CT053 for Multiple Myeloma Treatment

News

The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR T-cell therapies, for the treatment of patients with ... Read more

August 30, 2019September 16, 2019

European Commission Approves Empliciti Triple Combo for Advanced Multiple Myeloma

News

The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The therapy, ... Read more

Pin It on Pinterest